Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Peloton’s Bold Reset: Can New Hires & Smarter Spending Power A Comeback?
Peloton has hired a new leadership team and new CEO Peter Stern is implementing a multi-pronged turnaround strategy that targets cost reduction, new revenue channels, and improved customer retention.
Victoria’s Secret Under Siege: Activists Turn Up The Heat As Stock Flounders!
Bitcoin’s Key Drivers This Week: Powell’s Testimony, Core PCE Data, and Tariff Concerns
Stock Market Today: Dow, S&P 500, Nasdaq Waver After Report of Iranian Missile Strikes Aimed at US Air Bases
Business & Market Movers
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
·Jun 25, 2025
Stock Market Today: Stocks Rise as Trump Calls for Israel to Halt Strikes on Iran, Market Eyes Powell’s Testimony
·Jun 24, 2025
Forward Air On The Auction Block: Why Private Equity Titans Are Circling The $2.5 Billion Logistics Firm!
·Jun 24, 2025Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023
Deep Dive & Research
Healthcare & Biotech
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused on one-time therapies to lower cholesterol and prevent heart disease.
BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story
Tech & Energy
Is This The Beginning of the End for Google Search? Alphabet’s Future Hangs in the Balance!
Traditional search referrals are dropping across major categories like e-commerce, travel, and news, as more users migrate to AI-powered alternatives like OpenAI’s ChatGPT and Perplexity AI.
Meta’s $14.8 Billion AI Blitz: Inside Zuckerberg’s High-Stakes Superintelligence Gamble!
Arista Networks’ Stunning Reversal: From Avoided To Adored — Why Wall Street Sees Strong Upside Ahead!
How AMD’s Enosemi Acquisition Pushes It Deeper Into The Co-Packaged Optics & AI Arms Race!
